GW
ANIK icon

Glenn Welling’s Anika Therapeutics ANIK Stock Holding History

Glenn Welling’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-374,926
Closed -$12.6M – 13
2018
Q4 		$12.6M Sell
374,926
-12,000
-3% -$433K 2.34% 11
2018
Q3 		$16.3M Buy
386,926
+124,379
+47% +$4.91M 2.29% 9
2018
Q2 		$8.4M Buy
+262,547
New +$10.8M 1.06% 12

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Glenn Welling's ANIK Position: Q1 2019 in Review

Glenn Welling sold out of Anika Therapeutics (ANIK) in Q1 2019, closing a stake of 374,926 shares — an estimated $12.6M sold.

Glenn Welling first reported a position in ANIK in Q2 2018 and held it in 3 quarters. The position peaked at $16.3M in Q3 2018. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

  • Glenn Welling reported no remaining Anika Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Glenn Welling sold 374,926 Anika Therapeutics shares in Q1 2019, an estimated $12.6M.
  • Glenn Welling first reported a position in Anika Therapeutics in Q2 2018 and held it in 3 quarters.
  • Glenn Welling's Anika Therapeutics position peaked at $16.3M in Q3 2018.
  • 157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on Engaged Capital's 13F filing for Q1 2019, filed 15 May 2019.